Kestra Medical Technologies, Ltd. Selling, General and Administrative Expense
Kestra Medical Technologies, Ltd. (KMTS) reported Selling, General and Administrative Expense of $48.36 million for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-09-14
- Kestra Medical Technologies, Ltd. selling, general and administrative expense for the quarter ending 2026-07-31 was $48.36M, a 43.38% increase year-over-year.
- Kestra Medical Technologies, Ltd. selling, general and administrative expense for the quarter ending 2026-04-30 was $49.39M, a 2.11% decline year-over-year.
- Kestra Medical Technologies, Ltd. selling, general and administrative expense for the quarter ending 2026-01-31 was $42.70M, a 79.45% increase year-over-year.
- Kestra Medical Technologies, Ltd. selling, general and administrative expense for the quarter ending 2025-10-31 was $38.30M, a 78.52% increase year-over-year.
- Kestra Medical Technologies, Ltd. selling, general and administrative expense for fiscal 2026 was $164.12M, a 42.79% increase from fiscal 2025.
- Kestra Medical Technologies, Ltd. selling, general and administrative expense for fiscal 2025 was $114.94M, a 64.35% increase from fiscal 2024.
- Kestra Medical Technologies, Ltd. selling, general and administrative expense for fiscal 2024 was $69.94M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-07-31 | $48.36M 10-Q · filed 2026-09-14 | $97.75M derived: sum of 2 quarters · filed 2026-09-14 | $140.45M derived: sum of 3 quarters · filed 2026-09-14 | $178.75M derived: sum of 4 quarters · filed 2026-09-14 |
| 2026-04-30 | $49.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-14 | $92.09M derived: sum of 2 quarters · filed 2026-07-14 | $130.39M derived: sum of 3 quarters · filed 2026-07-14 | $164.12M 10-K · filed 2026-07-14 |
| 2026-01-31 | $42.70M 10-Q · filed 2026-03-17 | $81.00M derived: sum of 2 quarters · filed 2026-03-17 | $114.73M 10-Q · filed 2026-03-17 | $165.19M derived: sum of 4 quarters · filed 2026-09-14 |
| 2025-10-31 | $38.30M 10-Q · filed 2025-12-11 | $72.03M 10-Q · filed 2025-12-11 | $122.49M derived: sum of 3 quarters · filed 2026-09-14 | $146.28M derived: sum of 4 quarters · filed 2026-09-14 |
| 2025-07-31 | $33.73M 10-Q · filed 2026-09-14 | $84.19M derived: sum of 2 quarters · filed 2026-09-14 | $107.98M derived: sum of 3 quarters · filed 2026-09-14 | $129.44M derived: sum of 4 quarters · filed 2026-09-14 |
| 2025-04-30 | $50.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-14 | $74.25M derived: sum of 2 quarters · filed 2026-07-14 | $95.71M derived: sum of 3 quarters · filed 2026-07-14 | $114.94M 10-K · filed 2026-07-14 |
| 2025-01-31 | $23.80M 10-Q · filed 2026-03-17 | $45.25M derived: sum of 2 quarters · filed 2026-03-17 | $64.48M 10-Q · filed 2026-03-17 | |
| 2024-10-31 | $21.45M 10-Q · filed 2025-12-11 | $40.68M 10-Q · filed 2025-12-11 | ||
| 2024-07-31 | $19.23M 10-Q · filed 2025-09-12 | |||
| 2024-04-30 | $69.94M 10-K · filed 2025-07-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| LEMAITRE VASCULAR INC (LMAT) | United States | $1.848B | 33.37 |
| NovoCure Ltd (NVCR) | $1.886B | -11.87 | |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| Inspire Medical Systems, Inc. (INSP) | United States | $1.990B | 9.55 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |